# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Ascendiant Capital analyst Edward Woo maintains Aemetis (NASDAQ:AMTX) with a Buy and lowers the price target from $20 to $19.
UBS analyst Manav Gupta maintains Aemetis (NASDAQ:AMTX) with a Buy and lowers the price target from $8.25 to $7.75.
HC Wainwright & Co. analyst Amit Dayal reiterates Aemetis (NASDAQ:AMTX) with a Buy and maintains $28 price target.
Aemetis (NASDAQ:AMTX) reported quarterly losses of $(0.66) per share which missed the analyst consensus estimate of $(0.48) by ...
Truist Securities analyst Jordan Levy reiterates Aemetis (NASDAQ:AMTX) with a Hold and lowers the price target from $4 to $3.5.
Avian influenza continues to spread among animals and has infected four dairy workers in the US. Concerns about human-to-human ...
Truist Securities analyst Jordan Levy reiterates Aemetis (NASDAQ:AMTX) with a Hold and raises the price target from $3.5 to $4.